| Human immunodeficiency virus I infection
Sunlenca vs Tivicay
Side-by-side clinical, coverage, and cost comparison for human immunodeficiency virus i infection.Deep comparison between: Sunlenca vs Tivicay with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTivicay has a higher rate of injection site reactions vs Sunlenca based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Tivicay but not Sunlenca, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Sunlenca
Tivicay
At A Glance
SC injection
Every 6 months
HIV-1 capsid inhibitor
Oral
Once daily (or twice daily with certain inducers)
Integrase strand transfer inhibitor (INSTI)
Indications
- Human immunodeficiency virus I infection
- Human immunodeficiency virus I infection
Dosing
Human immunodeficiency virus I infection (Initiation Option 1) Day 1: 927 mg SC injection (2 x 1.5 mL) plus 600 mg oral (2 x 300 mg tablets); Day 2: 600 mg oral (2 x 300 mg tablets); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (Initiation Option 2) Days 1 and 2: 600 mg oral (2 x 300 mg tablets); Day 8: 300 mg oral (1 x 300 mg tablet); Day 15: 927 mg SC injection (2 x 1.5 mL); then 927 mg SC every 6 months (26 weeks) for maintenance.
Human immunodeficiency virus I infection (treatment-naive or INSTI-naive adults) 50 mg orally once daily, with or without food. Adjust to 50 mg twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (INSTI-experienced adults with resistance) 50 mg orally twice daily, with or without food, combined with optimized background therapy.
Human immunodeficiency virus I infection (pediatric patients 3 kg to <6 kg) TIVICAY PD 5 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 6 kg to <10 kg) TIVICAY PD 15 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 10 kg to <14 kg) TIVICAY PD 20 mg orally once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients 14 kg to <20 kg) TIVICAY PD 25 mg orally once daily or TIVICAY tablets 40 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (pediatric patients >=20 kg) TIVICAY PD 30 mg orally once daily or TIVICAY tablets 50 mg once daily. Adjust to twice daily if coadministered with UGT1A or CYP3A inducers.
Human immunodeficiency virus I infection (virologically suppressed adults switching to dual therapy) 50 mg orally once daily in combination with rilpivirine 25 mg once daily, with or without food.
Contraindications
- Concomitant use of strong CYP3A inducers
- Hypersensitivity to dolutegravir
- Coadministration with dofetilide
Adverse Reactions
Most common (>=3%) Injection site reactions, nausea
Serious Grade 3 injection site reactions (erythema, pain, swelling)
Postmarketing Injection site necrosis
Most common (>=2%, treatment-naive) Insomnia, headache, diarrhea, nausea, fatigue, rash
Serious Hypersensitivity reactions, hepatotoxicity, immune reconstitution syndrome
Postmarketing Sideroblastic anemia, acute liver failure, weight increased, arthralgia, myalgia, anxiety
Pharmacology
Lenacapavir is a multistage, selective HIV-1 capsid inhibitor that directly binds to capsid protein (p24) subunits in hexamers, inhibiting multiple essential steps of the viral lifecycle including capsid-mediated nuclear uptake of proviral DNA, virus assembly and release, and capsid core formation.
Dolutegravir is an HIV-1 integrase strand transfer inhibitor that blocks the strand transfer step of retroviral DNA integration essential for HIV replication by binding to the integrase active site.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Sunlenca
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (11/12)
Tivicay
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Sunlenca
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Tivicay
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
Sunlenca
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (3/3)
Tivicay
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0/fillfill
Gilead Advancing Access Co-Pay Program: SunlencaCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableGood Days: HIV, AIDS Treatment & Prevention
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SunlencaView full Sunlenca profile
TivicayView full Tivicay profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.